Healius Ltd (ASX: HLS) reported its FY19 results this morning, including a cut to its final dividend. Here’s what you need to know.
Healius, formerly known as Primary Health Care Limited (ASX: PRY), is a healthcare business that provides pathology, diagnostic imaging, medical centres and low-cost fertility services, such as IVF. It operates across thousands of sites Australia wide.
Here Are The Three Key Points
- Revenue grew 5.9% to $1,804.5 million, up from $1,704.6 million
- Underlying net profit after tax (NPAT) increased by 6.5% to $93.2 million
- A final dividend of 3.4 cents per share (cps) was declared, down from 5.5 cps in FY18
According to Bloomberg, analysts were estimating NPAT of $93.77 million and a dividend of 5.1 cents per share for Healius.
The actual NPAT result came in marginally lower than estimates, but it seems the dividend cut was not anticipated by analysts.
The reason that the dividend was cut from 5.5 cps to 3.4 cps is so that Healius can “provide an appropriate balance between the current capital investment phase, dividends and prudent gearing levels”.
The dividend cut means the full-year dividend will be 7.2 cps, compared to 10.6 cps in FY18. The final dividend is fully-franked and will be paid on 27th September 2019.
The pathology division, which is Healius’ largest division, saw relatively weak revenue growth of 3.9% in FY19. An increase in labour costs and the loss of a bowel screening contract resulted in EBIT being slightly below FY18.
The medical centres division saw much higher growth with EBIT up 19% to $37.6 million. Healius recruited a record 259 GPs during the year, a 63% growth on FY18 recruitments, resulting in a total of 1,164 GPs at 30th June 2019.
Imaging revenue grew by 7.9% to $391.3 million and EBIT was up 14.5% to $38.7 million.
Healius reported that FY20 underlying NPAT is expected to be higher than FY19 subject to market conditions. The report states that the underlying demand for healthcare in Australia is strong and driven by a growing and ageing population, as well as an increased life expectancy for many Australians living with chronic illness.
Is Healius A Buy?
While Healius has performed well and reported modest growth, the dividend cut is a concern. Healius currently trades on a trailing price-earnings (PE) ratio of 284 times, so I’m also unsure about the valuation.
For now, I’d rather invest in one of the businesses in the free report below.
Finding ASX shares offering exceptional long term growth and dividends over 3% is rare. Fortunately, the Rask Group's top expert investment analyst has released a FREE investing report which reveals 3 proven ASX shares.
These three companies have proven themselves to be reliable dividend + growth shares over a decade. Click here to get instant access to his report.
Past performance is not indicative of future performance but as he says in his report, there are many reasons to keep a close watch on these 3 shares in 2019 and beyond.
Absolutely no credit card details or payment required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
Disclosure: At the time of writing, Max does not own shares in any of the companies mentioned.